Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort

Abstract

Circulating IGFBP-1 and ghrelin measured during an OGTT predicted major health events and death in older adults, which may explain the influence of the GH/IGF-I axis on lifespan and health.

Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort

“…6 Low levels of IGFBP-1 are associated with the metabolic syndrome 18 and increased risk of developing CV disease in patients without diabetes, 7 but the prognostic value of IGFBP-1 in patients with an acute CV event without known diabetes is to the best of our knowledge not explored. Elevated levels of IGFBP-1 above the mean in healthy controls represent oxidative stress, inflammation, catabolism, malnutrition, 10,11 low insulin production and possibly renal impairment, 19 all factors that may hamper the prognosis in patients with an acute coronary event.…”

“…[6][7][8] Still, the relationship of IGFBP-1 and CV disease remains conflicting. Low levels of IGFBP-1 have been associated with future CV risk in patients with diabetes, 9 while high levels of IGFBP-1 seemed to be related to mortality in the elderly, 10 critically ill patients 11 and after an acute myocardial infarction (AMI) in patients with known diabetes. 12,13 Whether this also applies to individuals with AMI without known diabetes remains less well explored.…”

Body composition, appetite-related hormones, adipocytokines, and heart failure in adult patients with congenital heart disease: A preliminary study

“…In contrast, the mechanism underlying low ghrelin levels in adult patients with Fontan circulation and those with cyanosis is likely distinct. Ghrelin also has direct metabolic effects in the periphery, such as endopancreatic function and altered glucose metabolism . Intravenous ghrelin administration in humans has been demonstrated to promote a favorable effect on glucose metabolism, insulin sensitivity, and lipolysis inhibition .…”

“…Ghrelin also has direct metabolic effects in the periphery, such as endopancreatic function and altered glucose metabolism . Intravenous ghrelin administration in humans has been demonstrated to promote a favorable effect on glucose metabolism, insulin sensitivity, and lipolysis inhibition . Decreased ghrelin levels in patients with type 2 diabetes mellitus are associated with an increase in abdominal adiposity and insulin resistance .…”

“…30 Intravenous ghrelin administration in humans has been demonstrated to promote a favorable effect on glucose metabolism, insulin sensitivity, and lipolysis inhibition. [30][31][32] Decreased ghrelin levels in patients with type 2 diabetes mellitus are associated with an increase in abdominal adiposity and insulin resistance. [30][31][32] Overall, ghrelin as an AGR-conscious therapeutic strategy might also be associated with a significant reduction in cardiovascular events.…”